Home > Journals > Biology and research > Magnesium Research > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Biology and research
Magnesium Research
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Extracellular matrix disturbances in acute myocardial infarction: relation between disease severity and matrix metalloproteinase‐1, and effects of magnesium pretreatment on reperfusion injury


Magnesium Research. Volume 16, Number 2, 120-6, June 2003, ORIGINAL ARTICLE

Free Article  

Author(s) : Kenji Ueshima, Masashi Shibata, Tomomi Suzuki, Shigeatsu Endo, Katsuhiko Hiramori

Summary : Purpose: The purpose of this paper is to clarify the relationship between cytokines, matrix metalloproteinase‐1 (MMP‐1) and severity of acute myocardial infarction (AMI). Additionally, to investigate whether magnesium (Mg) sulfate pretreatment inhibits myocardial damage in coronary reperfusion therapy for patients with AMI. Subjects: At first, 34 patients with AMI were enrolled. Then, the patients were classified into 2 groups with or without congestive heart failure (CHF) (C group and NC group, respectively). Interleukin 6 (IL‐6), MMP‐1 and the hemodynamic parameters were measured. Second, 36 AMI patients treated with coronary reperfusion therapy were enrolled. Patients were divided into 2 groups (18 patients each) as the non‐pretreated group (Control group) and the group pretreated with intravenous Mg sulfate (0.27 mmol\\kg) (Mg group). IL‐6, MMP‐1 and the indexes of reperfusion injury were evaluated. Results: There were positive correlations between peak MMP‐1 level, and peak creatine kinase value and pulmonary capillary wedge pressure and peak IL‐6 level (r ∓ 0.43, r ∓ 0.70, and r ∓ 0.60, respectively) in all patients. There were negative correlations between peak MMP‐1 level and left ventricular ejection fraction and cardiac index (r ∓ ‐‐ 0.52 and r ∓ ‐‐ 0.55, respectively). The peak blood IL‐6 and MMP‐1 level increased in AMI, particularly in patients with CHF (C group vs NC group\; 130 vs 51 pg\\mL and 37 vs 18 ng\\mL, both p <\; 0.01). Additionally, peak IL‐6 and peak MMP‐1 in the Mg group were lower than those of the control group (39 vs 92 pg\\mL and 16 vs 20 ng\\mL, p <\; 0.05 and p ∓ 0.09, respectively). The incidence of reperfusion injury including reperfusion arrhythmia and transient exacerbation of ST elevation in the Mg group was lower than that of control group (17 vs 78% and 2.5 vs 4.7 mm, p <\; 0.01 and p ∓ 0.08, respectively). Conclusion: These results may suggest that the severity of AMI is reflected by the blood IL‐6 and MMP‐1 levels and that pretreatment with Mg administration protects the myocardium of patients with AMI from reperfusion injury induced by IL‐6 and MMP‐1.

Keywords : matrix metalloproteinase‐1, magnesium, acute myocardial infarction, reperfusion therapy.

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]